Transaction in Own Shares

RNS Number : 0361N

Hikma Pharmaceuticals Plc

02 September 2013

 



Hikma Pharmaceuticals PLC

Transaction in Own Shares

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (the "Company") announces that on 30 August 2013 it purchased 35,000 of its ordinary shares of £0.10 each at an average price of £10.147 per share (the "Share Buy-Back").

The highest price paid for a share was £10.14 and the lowest price paid for a share was £10.15.

The shares purchased pursuant to the Share Buy-Back will be held as treasury shares.

Following the Share Buy-Back the Company holds a total of 210,000 ordinary shares of £0.10 each as treasury shares and has 197,731,128 ordinary shares of £0.10 each in issue (excluding those shares held as treasury shares).

Any shares purchased under the Share Buy-back will count towards the Company's general buy-back authority of approximately 10% of the Company's issued share capital (aggregate nominal amount equal to £1,974,844), as approved at the Company's Annual General Meeting on 16 May 2013.

The total number of voting rights in the Company, excluding treasury shares, as at 30 August 2013 is 197,731,128. This figure may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million. 

 

END

 

 

POSZLLFBXKFBBBX